Avatar

Dominic Magirr

Medical Statistician

Novartis

Biography

I’m a medical statistician interested in the design, analysis and interpretation of clinical trials.

Specific research interests include:

  • group sequential trials
  • multiple hypothesis testing
  • adaptive designs
  • survival analysis

Since February 2020 I have been working in the Statistical Methodology Group at Novartis in Basel.

Recent Posts

The MaxCombo Test severely inflates the type 1 error rate

“The MaxCombo Test severely inflates the type 1 error rate”, by Carl-Fredrik Burman and myself has just been published in JAMA …
Last updated on Oct 17, 2022 9 min read

{nphRCT} on CRAN

I’m delighted that our new R package {nphRCT} is available on CRAN. Special thanks to Isobel Barrot. Her R skills have made this …
Last updated on Sep 1, 2022 6 min read

Pseudo-observations 2

This is a quick follow up to my previous post on pseudo-observations where I reproduced Table 1 from “Causal inference in survival …
Last updated on Jul 4, 2022 5 min read

Pseudo observations on pseudo-observations

Idea / motivation I’ve set myself the challenge of reproducing the results in Table I of “Causal inference in survival analysis using …
Last updated on Jul 1, 2022 9 min read

Conditional and unconditional treatment effects in RCTs

Small simulation study Quick function to simulate data from an RCT with equal allocation to treatments 0 and 1, a single covariate, and …
Last updated on May 25, 2022 4 min read
See all posts

Recent & Upcoming Talks

Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups

In this talk I delved into some of the history of John Whitehead’s Triangular Test. The context was a mulit-arm trial of several …
Sep 26, 2018 12:00 PM LSHTM
PDF

Group-sequential and adaptive designs in immuno-oncology

Here I talk about designing a clinical trial for an immuno-oncology endpoint where we expect a delay in the seperation of the survival …
Jun 4, 2018 2:00 PM Amsterdam
Slides

Small trials, historical data. Methods and software for decision making.

Quite often, single-arm studies in early-phase oncology are criticized because they lead to false positives. Here, I wanted to point …
Aug 30, 2017 9:30 AM Vienna
PDF